Amundi
CPRX

Amundi’s Catalyst Pharmaceutical CPRX Stock Holding History

Amundi’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
33,560
+2,097
+7% +$61.9K ﹤0.01% 1351
2026
Q1 		$779K Buy
31,463
+12,778
+68% +$304K ﹤0.01% 1373
2025
Q4 		$436K Sell
18,685
-1,845
-9% -$41.1K ﹤0.01% 1528
2025
Q3 		$426K Buy
20,530
+1,843
+10% +$37.9K ﹤0.01% 1372
2025
Q2 		$401K Sell
18,687
-26,444
-59% -$624K ﹤0.01% 1432
2025
Q1 		$1.09M Sell
45,131
-11,478
-20% -$258K ﹤0.01% 1310
2024
Q4 		$1.29M Buy
56,609
+36,968
+188% +$794K ﹤0.01% 1339
2024
Q3 		$394K Buy
19,641
+2,905
+17% +$53.9K ﹤0.01% 1490
2024
Q2 		$256K Sell
16,736
-2,926
-15% -$45.6K ﹤0.01% 1519
2024
Q1 		$302K Buy
19,662
+6,503
+49% +$98K ﹤0.01% 1542
2023
Q4 		$201K Buy
13,159
+616
+5% +$8.42K ﹤0.01% 1631
2023
Q3 		$160K Buy
12,543
+1
+0% +$13 ﹤0.01% 1650
2023
Q2 		$160K Buy
+12,542
New +$180K ﹤0.01% 1663

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Amundi's CPRX Position: Q2 2026 in Review

Amundi increased its Catalyst Pharmaceutical (CPRX) stake by 6.7% in Q2 2026, buying an estimated $61.9K and bringing the position to 33,560 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1351.

Amundi first reported a position in CPRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.29M in Q4 2024. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Amundi held 33,560 shares of Catalyst Pharmaceutical worth $1.05M as of Q2 2026.
  • Amundi bought 2,097 Catalyst Pharmaceutical shares in Q2 2026, an estimated $61.9K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1351 holding.
  • Amundi first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
  • Amundi's Catalyst Pharmaceutical position peaked at $1.29M in Q4 2024.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.